Bristol Company Profile

What is the competitive landscape for BRISTOL, and when can generic versions of BRISTOL drugs launch?

BRISTOL has one hundred and sixteen approved drugs.

There are fifty-five US patents protecting BRISTOL drugs.

There are one thousand six hundred and ninety-one patent family members on BRISTOL drugs in fifty-eight countries and three hundred and nine supplementary protection certificates in nineteen countries.

Summary for Bristol

International Patents:	1691
US Patents:	55
Tradenames:	93
Ingredients:	81
NDAs:	116
Drug Master File Entries:	1
Patent Litigation for Bristol:	See patent lawsuits for Bristol
PTAB Cases with Bristol as patent owner:	See PTAB cases with Bristol as patent owner

Drugs and US Patents for Bristol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-004	Jun 29, 2006	AB	RX	Yes	Yes
Bristol	ZEPOSIA	ozanimod hydrochloride	CAPSULE;ORAL	209899-002	Mar 25, 2020		RX	Yes	No	8,481,573		Y	Y
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-004	Apr 28, 2022		RX	Yes	No
Bristol	VIDEX	didanosine	FOR SOLUTION;ORAL	020156-001	Oct 9, 1991		DISCN	Yes	No
Bristol Myers Squibb	BLENOXANE	bleomycin sulfate	INJECTABLE;INJECTION	050443-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Bristol Myers Squibb	AMNESTROGEN	estrogens, esterified	TABLET;ORAL	083266-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Bristol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-002	Sep 17, 1998	6,555,133*PED
Bristol Myers Squibb	VIDEX	didanosine	FOR SOLUTION;ORAL	020155-004	Oct 9, 1991	4,861,759*PED
Bristol Myers Squibb	PRAVACHOL	pravastatin sodium	TABLET;ORAL	019898-003	Oct 31, 1991	5,622,985*PED
Bristol	POMALYST	pomalidomide	CAPSULE;ORAL	204026-001	Feb 8, 2013	8,589,188
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005	6,096,331
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998	6,561,977

Paragraph IV (Patent) Challenges for BRISTOL drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	5 mg, 10 mg and 15 mg		2010-08-30
	For Injection Suspension	100 mg/vial		2015-12-11
	Capsules	300 mg		2009-07-20
	Capsules	200 mg		2010-02-16
	Capsules	50 mg, 100 mg and 200 mg		2016-11-03
	Tablets	0.5 mg and 1 mg		2010-06-14
	Tablets	30 mg		2005-06-01
	Tablets	80 mg and 140 mg		2011-06-16
	Capsules	1 mg, 2 mg, 3 mg and 4 mg		2017-02-08
	Capsules	50 mg and 100 mg		2006-12-18
	Capsules	25 mg		2010-07-12
	Capsules	150 mg		2014-02-03
	Capsules	2.5 mg and 20 mg		2016-07-12
	Injection	10 mg/vial		2013-11-05
	Capsules	100 mg and 150 mg		2010-03-19
	Tablets	600 mg		2009-04-09
	Nasal Spray	4 mg/spray		2016-07-15
	Tablets	2.5 mg and 5 mg		2016-12-28
	Tablets	20 mg, 50 mg, 70 mg and 100 mg		2010-06-28
	Tablets	80 mg and 140 mg		2011-06-17
	Delayed-release Capsules	200 mg, 250 mg and 400 mg		2004-06-01
	Capsules	200 mg		2006-09-25

International Patents for Bristol Drugs

Country	Patent Number	Estimated Expiration
Argentina	071808
Luxembourg	92864
Denmark	3042901
China	1578660
China	102118972
South Korea	20200038337

Supplementary Protection Certificates for Bristol Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3150586	2090020-5	Sweden		PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, DARUNAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR DARUNAVIR ETHANOLATE, AND EMTRICITABINE OR A PHARMACEUTICALLY ACCEBTABLE SALT OR SOLVATE THEREOF; REG. NO/DATE: EU/1/17/1225 20170925
0481754	33/2006	Austria		PRODUCT NAME: ENTECAVIR UND DESSEN HYDRATE; REGISTRATION NO/DATE: EU/1/06/343/001- EU/1/06/343/005 20060626
1353647	C300492	Netherlands		PRODUCT NAME: AZTREONAM, NIET IN EEN SAMENSTELLING MET ARGININE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN AZTREONAM, ANDERS DAN EEN ARGININEZOUT, IN HET BIJZONDER ALS AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090921
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
1951684	LUC00204	Luxembourg		PRODUCT NAME: FEDRATINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR A PHARMACEUTICALLY ACCEPTABLE HYDRATE THEREOF, IN PARTICULAR FEDRATINIB DIHYDROCHLORIDE MONOHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/20/1514 20210209
1951684	SPC/GB21/026	United Kingdom		PRODUCT NAME: FEDRATINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR A PHARMACEUTICALLY ACCEPTABLE HYDRATE THEREOF, IN PARTICULAR FEDRATINIB DIHYDROCHLORIDE MONOHYDRATE; REGISTERED: UK EU/1/20/1514(FOR NI) 20210209; UK FURTHER MA ON IPSUM 20210209

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bristol
• Bristol Myers
• Bristol Myers Squibb
• Bristol-myers
• Bristol-myers Squibb